Denali Therapeutics Swings to Profit in Q3

Denali Therapeutics announced its financial results for the third quarter ended September 30, 2026, reporting net income of $70.1 million, which included a one-time $194.0 million gain from the sale of a Priority Review Voucher. The company achieved $17.8 million in net product revenue for its product AVLAYAH, surpassing the FactSet consensus estimate of $12.2 million. Earnings per share were $0.37, compared to an expected loss of $0.31. Management provided fourth-quarter 2026 revenue guidance in the range of $30.0 million to $32.0 million. Additionally, the company highlighted that AVLAYAH coverage now exceeds 70% of U.S. commercial lives and a permanent J-code for the product became effective on October 1, 2026.